Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susanne Zielke

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Ugeskrift for Laeger|March 22, 2012
[Clinical pathways for rehabilitation of adults with acquired brain injury]Hysse B Forchhammer, Peter Vögele, Susanne Zielke, et al.
Ugeskrift for Laeger|October 20, 2012
[Danish Apoplexy Registry]Søren Paaske Johnsen, Annette Ingeman, Susanne Zielke, et al.
Clinical Epidemiology|November 16, 2016
The Danish Stroke RegistrySøren Paaske Johnsen, Annette Ingeman, Heidi Holmager Hundborg, et al.
Medical Care|December 29, 2007
Quality of care and mortality among patients with stroke: a nationwide follow-up studyAnnette Ingeman, Lars Pedersen, Heidi H Hundborg, et al.
Orphanet Journal of Rare Diseases|September 29, 2021
HAE patient self-sampling for biomarker establishmentToni M Förster, Markus Magerl, Marcus Maurer, et al.
Scientific Reports|July 23, 2017
C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber DiseaseClaudia Cozma, Marius-Ionuț Iurașcu, Sabrina Eichler, et al.
Journal of Clinical Medicine|October 26, 2024
Hereditary Transthyretin-Related Amyloidosis Ongoing Observational Study: A Baseline Report of the First 3167 ParticipantsSabine Rösner, Luba M Pardo, Aida M Bertoli-Avella, et al.
Clinical Genetics|January 12, 2019
Clinical, biomarker and genetic spectrum of Niemann-Pick type C in Egypt: The detection of nine novel NPC1 mutationsIman G Mahmoud, Mohamed A Elmonem, Nour M Elkhateeb, et al.
Diagnostics (Basel, Switzerland)|September 9, 2023
Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF StudyFilipa Curado, Sabine Rösner, Susanne Zielke, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Ugeskrift for Laeger|March 22, 2012
[Clinical pathways for rehabilitation of adults with acquired brain injury]Hysse B Forchhammer, Peter Vögele, Susanne Zielke, et al.
Ugeskrift for Laeger|October 20, 2012
[Danish Apoplexy Registry]Søren Paaske Johnsen, Annette Ingeman, Susanne Zielke, et al.
Clinical Epidemiology|November 16, 2016
The Danish Stroke RegistrySøren Paaske Johnsen, Annette Ingeman, Heidi Holmager Hundborg, et al.
Medical Care|December 29, 2007
Quality of care and mortality among patients with stroke: a nationwide follow-up studyAnnette Ingeman, Lars Pedersen, Heidi H Hundborg, et al.
Orphanet Journal of Rare Diseases|September 29, 2021
HAE patient self-sampling for biomarker establishmentToni M Förster, Markus Magerl, Marcus Maurer, et al.
Scientific Reports|July 23, 2017
C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber DiseaseClaudia Cozma, Marius-Ionuț Iurașcu, Sabrina Eichler, et al.
Journal of Clinical Medicine|October 26, 2024
Hereditary Transthyretin-Related Amyloidosis Ongoing Observational Study: A Baseline Report of the First 3167 ParticipantsSabine Rösner, Luba M Pardo, Aida M Bertoli-Avella, et al.
Clinical Genetics|January 12, 2019
Clinical, biomarker and genetic spectrum of Niemann-Pick type C in Egypt: The detection of nine novel NPC1 mutationsIman G Mahmoud, Mohamed A Elmonem, Nour M Elkhateeb, et al.
Diagnostics (Basel, Switzerland)|September 9, 2023
Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF StudyFilipa Curado, Sabine Rösner, Susanne Zielke, et al.
Pageof 1